The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 07, 2020
Filed:
Jul. 12, 2018
Applicant:
University of Tennessee Research Foundation, Knoxville, TN (US);
Inventors:
Jin Wang, Memphis, TN (US);
Jianjun Chen, Knoxville, TN (US);
Duane D. Miller, Collierville, TN (US);
Wei Li, Germantown, TN (US);
Assignee:
UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION, Knoxville, TN (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4178 (2006.01); A61K 31/337 (2006.01); A61K 31/437 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/4174 (2006.01); A61K 31/42 (2006.01); A61K 31/335 (2006.01); A61K 31/4164 (2006.01); A61K 31/435 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4178 (2013.01); A61K 31/337 (2013.01); A61K 31/4174 (2013.01); A61K 31/437 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/335 (2013.01); A61K 31/4164 (2013.01); A61K 31/42 (2013.01); A61K 31/435 (2013.01);
Abstract
The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.